Showing results (1-10 of 42) with videos related to
Sort By:
Pageof 5
Deutsche Medizinische Wochenschrift (1946)|June 8, 1984
[Demonstration and occurrence of IgM-type hepatitis A viral antibodies]N Scheiermann, E KuwertVaccine|April 1, 1995
Quantification of hepatitis B vaccine-induced antibodies as a predictor of anti-HBs persistenceM Gesemann, N ScheiermannZentralblatt Fur Bakteriologie : International Journal of Medical Microbiology|February 1, 1993
Anti-HBs antibody kinetics--a 4-year follow-up after hepatitis B vaccinationN Scheiermann, M GesemannDevelopments in Biological Standardization|January 1, 1979
Purity, anticomplementary activity, and viral antibody profile of NIG preparations for intravenous and intramuscular useN Scheiermann, E K KuwertZentralblatt Fur Bakteriologie, Mikrobiologie, Und Hygiene. Series A, Medical Microbiology, Infectious Diseases, Virology, Parasitology|August 1, 1984
Active hepatitis B immunization with an experimental German vaccine. I. Immunogenicity studies in healthy adults. II. The primary 19 S and 7 S responses to HBsAg in healthy adults. III. Immunogenicity studies in hemodialysis patientsN Scheiermann, E K KuwertZentralblatt Fur Bakteriologie, Mikrobiologie, Und Hygiene. Series A, Medical Microbiology, Infectious Diseases, Virology, Parasitology|August 1, 1984
Active hepatitis B immunization with an experimental German vaccine. IV. Reactogenicity studies in healthy adults and in hemodialysis patientsN Scheiermann, E K KuwertDeutsche Medizinische Wochenschrift (1946)|December 17, 1982
[Uptake and elimination of hepatitis B immunoglobulin after intramuscular administration]N Scheiermann, E K KuwertMedizinische Klinik|May 25, 1979
[Studies on human immunoglobulin preparations: II. Purity and composition (author's transl)]N Scheiermann, E K KuwertDevelopments in Biological Standardization|January 1, 1983
Uptake and elimination of hepatitis B immunoglobulins after intramuscular application in manN Scheiermann, E K KuwertFortschritte Der Medizin|January 17, 1980
[Passive immunization against hepatitis B: state of development, comments and recommendations for clinical use]N Scheiermann, E K KuwertPageof 5